Vanlandigham B D, Brubaker R F
Mayo Medical School, Rochester, Minnesota, USA.
Am J Ophthalmol. 1998 Aug;126(2):191-6. doi: 10.1016/s0002-9394(98)00155-x.
To determine whether latanoprost, an ocular hypotensive agent believed to enhance uveoscleral outflow of aqueous humor, augments the aqueous-suppressing effect of dorzolamide, a topical carbonic anhydrase inhibitor.
Twenty-four normal subjects underwent measurement of aqueous humor flow by fluorophotometry to determine the flow with placebo, with dorzolamide, and with a combination of dorzolamide and latanoprost.
The flow of aqueous humor was suppressed 13% by dorzolamide but not by latanoprost. Latanoprost did not augment the effect of dorzolamide on aqueous humor flow; latanoprost and dorzolamide had additive ocular hypotensive effects.
The uveoscleral flow effect of latanoprost does not improve the aqueous-suppressing effect of dorzolamide, but the two drugs have additive ocular hypotensive effects.
确定拉坦前列素（一种被认为可增强房水经葡萄膜巩膜外流的降眼压药物）是否能增强局部碳酸酐酶抑制剂多佐胺的房水抑制作用。
24名正常受试者通过荧光光度法测量房水流量，以确定使用安慰剂、多佐胺以及多佐胺与拉坦前列素联合使用时的房水流量。
多佐胺可使房水流量降低13%，但拉坦前列素无此作用。拉坦前列素并未增强多佐胺对房水流量的作用；拉坦前列素和多佐胺具有相加的降眼压作用。
拉坦前列素的葡萄膜巩膜引流效应并未改善多佐胺的房水抑制作用，但这两种药物具有相加的降眼压作用。
